We examined the effect of metoprolol controlled release/extended release (CR/XL) in 898 female patients participating in the Metoprolol CR/XL Randomized Intervention Trial in Heart Failure. There was a 21 reduction in the primary end points of total mortality and all-cause hospitalization. There was also a decrease in all-cause (15%), cardiovascular-cause (29%), and heart-failure hospitalization (42%). These data show the therapeutic benefit of beta blocking agents in women with heart failure.
|Original language||English (US)|
|Number of pages||4|
|State||Published - Oct 1 2002|
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine